Pub Date : 2024-10-30DOI: 10.1016/j.clbc.2024.10.017
Hannah Bacon, Ezra Hahn
{"title":"Another Biosignature for Ductal Carcinoma In Situ-Have We Moved the Needle?","authors":"Hannah Bacon, Ezra Hahn","doi":"10.1016/j.clbc.2024.10.017","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.017","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28DOI: 10.1016/j.clbc.2024.10.014
Aynur Aktas, Rebecca Sheaff Greiner, Matthew Flores, Danielle Boselli, Taylor Stone, Eric Wang, Lejla Hadzikadic-Gusic, Michelle L Wallander, Anna Hecksher, Chasse Bailey-Dorton, Declan Walsh
Background: Low skeletal muscle mass and poor muscle quality are associated with poor outcomes in women with breast cancer. However, gaps exist in our understanding of prognostic factors for young women (≤ 40 years), as they often have different body composition than older women. We evaluated pretreatment body composition measures in young women with breast cancer, including associations with overall survival (OS) and progression-free survival (PFS).
Methods: The Young Women's Database at Levine Cancer Institute was queried for women aged 18 to 40 at diagnosis (2009-2018) of single primary breast cancer (N = 870); patients with Stage 0 and 4 were excluded. Deceased patients with pretreatment computed tomography (CT) scans were identified (N = 40) and matched (1:1) to patients presumed alive by age, diagnosis year, and disease characteristics. CT-derived body composition measures included skeletal muscle index (SMI) and intramuscular adipose tissue corrected (IMAT-C). Sarcopenia (low muscle mass) was defined as SMI<40.
Results: Of 80 subjects, median age at diagnosis was 35 years. Median follow-up 8.6 years. Total 33% had low muscle mass (sarcopenic), and 56% had poor muscle quality (high IMAT-C). Independent of age, clinical disease stage, and primary insurer, high IMAT-C was associated with shorter PFS (HR 2.33, 95% CI 1.15-4.72; P = .020).
Conclusions: Poor muscle quality at diagnosis was associated with shorter progression-free survival in young women with breast cancer. Future research should determine the significance of changes in muscle quality throughout treatment.
{"title":"Association of Skeletal Muscle Mass and Muscle Quality at Diagnosis With Survival in Young Women With Breast Cancer: Retrospective Observational Study.","authors":"Aynur Aktas, Rebecca Sheaff Greiner, Matthew Flores, Danielle Boselli, Taylor Stone, Eric Wang, Lejla Hadzikadic-Gusic, Michelle L Wallander, Anna Hecksher, Chasse Bailey-Dorton, Declan Walsh","doi":"10.1016/j.clbc.2024.10.014","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.014","url":null,"abstract":"<p><strong>Background: </strong>Low skeletal muscle mass and poor muscle quality are associated with poor outcomes in women with breast cancer. However, gaps exist in our understanding of prognostic factors for young women (≤ 40 years), as they often have different body composition than older women. We evaluated pretreatment body composition measures in young women with breast cancer, including associations with overall survival (OS) and progression-free survival (PFS).</p><p><strong>Methods: </strong>The Young Women's Database at Levine Cancer Institute was queried for women aged 18 to 40 at diagnosis (2009-2018) of single primary breast cancer (N = 870); patients with Stage 0 and 4 were excluded. Deceased patients with pretreatment computed tomography (CT) scans were identified (N = 40) and matched (1:1) to patients presumed alive by age, diagnosis year, and disease characteristics. CT-derived body composition measures included skeletal muscle index (SMI) and intramuscular adipose tissue corrected (IMAT-C). Sarcopenia (low muscle mass) was defined as SMI<40.</p><p><strong>Results: </strong>Of 80 subjects, median age at diagnosis was 35 years. Median follow-up 8.6 years. Total 33% had low muscle mass (sarcopenic), and 56% had poor muscle quality (high IMAT-C). Independent of age, clinical disease stage, and primary insurer, high IMAT-C was associated with shorter PFS (HR 2.33, 95% CI 1.15-4.72; P = .020).</p><p><strong>Conclusions: </strong>Poor muscle quality at diagnosis was associated with shorter progression-free survival in young women with breast cancer. Future research should determine the significance of changes in muscle quality throughout treatment.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28DOI: 10.1016/j.clbc.2024.10.016
Yongqing Zhang, Mingjie Zhang, Guoxiu Yu, Wenhui Wang
Background: Breast cancer brain metastasis (BCBM) prognosis has not been evaluated dynamically, which may underestimate patient survival. This study aimed to perform a conditional survival (CS) analysis and develop and validate an individualized real-time prognostic monitoring model for survivors.
Methods: The study included patients with BCBM from the Surveillance, Epidemiology, and End Results database (training group, n = 998) and our institution (validation group, n = 45) and updated patient overall survival (OS) over time using the CS method: CS(t2|t1)=OS(t1+t2)OS(t1). Multivariate Cox regression was used to identify prognostic factors for the nomogram, which estimated individualized OS. Furthermore, a novel CS-nomogram and its web version were further developed based on the CS formula.
Results: CS analysis showed that the 5-year OS of BCBM survivors gradually improved from 13.5% estimated at diagnosis to 26.0%, 39.7%, 57.9%, and 77.6% (surviving 1-4 years, respectively). Cox regression identified age, marital status, estrogen receptor status, human epidermal growth factor receptor 2 (Her-2) status, histological grade, surgery, and chemotherapy as significant factors influencing OS (P < .05). We then constructed and deployed the CS-nomogram based on the CS formula and the nomogram to predict real-time prognosis dynamically (https://wh-wang.shinyapps.io/BCBM/). During performance evaluation, the model performed well in both the training and validation groups.
Conclusions: CS analysis showed a gradual improvement in prognosis over time for BCBM survivors. We developed and deployed on the web a novel real-time dynamic prognostic monitoring system, the CS-nomogram, which provided valuable survival data for clinical decision-making, patient counseling, and optimal allocation of healthcare resources.
{"title":"Development and Validation of a Novel Conditional Survival Nomogram for Predicting Real-Time Prognosis in Patients With Breast Cancer Brain Metastasis.","authors":"Yongqing Zhang, Mingjie Zhang, Guoxiu Yu, Wenhui Wang","doi":"10.1016/j.clbc.2024.10.016","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.016","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer brain metastasis (BCBM) prognosis has not been evaluated dynamically, which may underestimate patient survival. This study aimed to perform a conditional survival (CS) analysis and develop and validate an individualized real-time prognostic monitoring model for survivors.</p><p><strong>Methods: </strong>The study included patients with BCBM from the Surveillance, Epidemiology, and End Results database (training group, n = 998) and our institution (validation group, n = 45) and updated patient overall survival (OS) over time using the CS method: CS(t2|t1)=OS(t1+t2)OS(t1). Multivariate Cox regression was used to identify prognostic factors for the nomogram, which estimated individualized OS. Furthermore, a novel CS-nomogram and its web version were further developed based on the CS formula.</p><p><strong>Results: </strong>CS analysis showed that the 5-year OS of BCBM survivors gradually improved from 13.5% estimated at diagnosis to 26.0%, 39.7%, 57.9%, and 77.6% (surviving 1-4 years, respectively). Cox regression identified age, marital status, estrogen receptor status, human epidermal growth factor receptor 2 (Her-2) status, histological grade, surgery, and chemotherapy as significant factors influencing OS (P < .05). We then constructed and deployed the CS-nomogram based on the CS formula and the nomogram to predict real-time prognosis dynamically (https://wh-wang.shinyapps.io/BCBM/). During performance evaluation, the model performed well in both the training and validation groups.</p><p><strong>Conclusions: </strong>CS analysis showed a gradual improvement in prognosis over time for BCBM survivors. We developed and deployed on the web a novel real-time dynamic prognostic monitoring system, the CS-nomogram, which provided valuable survival data for clinical decision-making, patient counseling, and optimal allocation of healthcare resources.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-26DOI: 10.1016/j.clbc.2024.10.011
Hend Samir Ibrahim, Salman M Albeshan, Manal Ahmed ElRefaei
Objective: This study aimed to enhance outcomes for women undergoing breast cancer screening in a low utilization setting by implementing structured improvement cycles.
Methods: Improvement cycles were conducted using the Plan-Do-Study-Act (PDSA) methodology. Three cycles were implemented: (1) dedicating a specific day for breast screening and increasing appointment slots; (2) establishing a breast screening clinic with same-day registration; and (3) introducing a breast surgery clinic to expedite biopsy procedures for BI-RADS-4 category cases.
Results: Following each improvement cycle, dramatic increases in patient attendance were observed. In 2021, there was a 67.5% rise compared to the previous year, and a 72% increase in 2022 compared to 2021 figures. Patient characteristics revealed that 60% of attendees were new patients, with 53% of cancer and precancerous cases observed in women below 50 years old. Before the third cycle, the estimated diagnosis turnaround time (TAT) showed that only 23% of patients had their biopsy completed within 5 working days. However, after the third cycle (n = 131), 63.5% of biopsies were done within five working days.
Conclusion: Structured improvement cycles guided by the PDSA methodology effectively enhanced breast cancer screening outcomes. These cycles led to increased patient attendance, expedited biopsy procedures, and improved access to timely diagnosis. The findings highlight the importance of systematic approaches in optimizing breast cancer screening and improving patient care.
{"title":"Transforming Breast Cancer Care and Clinical Outcomes: Local Experience in Yanbu Industrial City, Saudi Arabia.","authors":"Hend Samir Ibrahim, Salman M Albeshan, Manal Ahmed ElRefaei","doi":"10.1016/j.clbc.2024.10.011","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.011","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to enhance outcomes for women undergoing breast cancer screening in a low utilization setting by implementing structured improvement cycles.</p><p><strong>Methods: </strong>Improvement cycles were conducted using the Plan-Do-Study-Act (PDSA) methodology. Three cycles were implemented: (1) dedicating a specific day for breast screening and increasing appointment slots; (2) establishing a breast screening clinic with same-day registration; and (3) introducing a breast surgery clinic to expedite biopsy procedures for BI-RADS-4 category cases.</p><p><strong>Results: </strong>Following each improvement cycle, dramatic increases in patient attendance were observed. In 2021, there was a 67.5% rise compared to the previous year, and a 72% increase in 2022 compared to 2021 figures. Patient characteristics revealed that 60% of attendees were new patients, with 53% of cancer and precancerous cases observed in women below 50 years old. Before the third cycle, the estimated diagnosis turnaround time (TAT) showed that only 23% of patients had their biopsy completed within 5 working days. However, after the third cycle (n = 131), 63.5% of biopsies were done within five working days.</p><p><strong>Conclusion: </strong>Structured improvement cycles guided by the PDSA methodology effectively enhanced breast cancer screening outcomes. These cycles led to increased patient attendance, expedited biopsy procedures, and improved access to timely diagnosis. The findings highlight the importance of systematic approaches in optimizing breast cancer screening and improving patient care.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The COVID-19 pandemic exposed significant challenges in breast cancer care including healthcare inequities, limited access to surgeries, and difficulties in delivering virtual care. This letter builds upon the findings from the article "The Impact of COVID-19 on Breast Cancer Care" and proposes innovative solutions to address these challenges. Key suggestions include the use of AI-powered digital platforms for remote monitoring, robotic-assisted surgery for enhanced precision, mobile health applications for marginalized populations, and 3D printing for personalized breast reconstruction. Additionally, wearable health devices, nanotechnology for targeted drug delivery, and blockchain for secure medical data sharing are proposed to further improve the future of breast cancer care. These innovations offer practical approaches to overcoming the obstacles highlighted during the pandemic and aim to create a more equitable and efficient healthcare system.
COVID-19 大流行暴露了乳腺癌护理面临的重大挑战,包括医疗保健不公平、手术机会有限以及提供虚拟护理的困难。这封信以《COVID-19 对乳腺癌护理的影响》一文的研究结果为基础,提出了应对这些挑战的创新解决方案。主要建议包括使用人工智能驱动的数字平台进行远程监控、使用机器人辅助手术提高精准度、为边缘化人群提供移动医疗应用,以及使用 3D 打印技术进行个性化乳房重建。此外,还提出了可穿戴健康设备、用于靶向给药的纳米技术以及用于安全医疗数据共享的区块链,以进一步改善乳腺癌护理的未来。这些创新提供了切实可行的方法,以克服大流行病期间凸显的障碍,并旨在创建一个更加公平和高效的医疗保健系统。
{"title":"Letter to the Editor Regarding the Article \"The Impact of COVID-19 on Breast Cancer Care: A Qualitative Analysis of Surgeons' Perspectives\".","authors":"Akshaya Viswanathan, Pitchaipillai Sankar Ganesh, Naji Naseef Pathoor, Rajesh Kanna Gopal","doi":"10.1016/j.clbc.2024.10.015","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.015","url":null,"abstract":"<p><p>The COVID-19 pandemic exposed significant challenges in breast cancer care including healthcare inequities, limited access to surgeries, and difficulties in delivering virtual care. This letter builds upon the findings from the article \"The Impact of COVID-19 on Breast Cancer Care\" and proposes innovative solutions to address these challenges. Key suggestions include the use of AI-powered digital platforms for remote monitoring, robotic-assisted surgery for enhanced precision, mobile health applications for marginalized populations, and 3D printing for personalized breast reconstruction. Additionally, wearable health devices, nanotechnology for targeted drug delivery, and blockchain for secure medical data sharing are proposed to further improve the future of breast cancer care. These innovations offer practical approaches to overcoming the obstacles highlighted during the pandemic and aim to create a more equitable and efficient healthcare system.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-23DOI: 10.1016/j.clbc.2024.10.007
Edmundo Gónima Valero, Cristian D Rodríguez Miranda, Sandra Contreras Arrieta, Maria I Daza Morelli, Daniela Seija Butnaru, Mariana Reyes Carrillo, Laura D Aponte Camacho, Sebastian Amaya
Objective: Literature regarding nonpharmacological interventions (NPI) for PMPS or CP after mastectomy is scarce and not fully appraised, therefore we conducted this systematic review to explore the current panorama of treatment options.
Methods: A systematic review to assess the existing evidence regarding nonpharmacological approaches for PMPS. We reviewed the following databases: PubMed-MEDLINE, Embase, and Ovid (including the Cochrane Database for Clinical studies) using the following search terms: CP, mastectomy, and PMPS, and adjusted the terms depending on the database used. We included observational studies including case reports, cross sectional studies, cohort studies, and clinical trials (randomized or not) that included a NPI to treat PMPS.
Results: Total 1061 records were identified. After duplicate elimination, 863 records were screened for eligibility. A total of 717 records were excluded using our criteria, 138 records were sought for retrieval, and 117 full text records were assessed. Finally, 30 studies were included: seven case series, one cross-sectional study, two cohort studies, one case-control study, five nonrandomized clinical trials, ten randomized clinical trials (RCT), one qualitative study, and three systematic reviews of the literature, including two meta analyses, were included.
Discussion: Findings suggest that there is a great response of patients to some NPI. Regarding surgical interventions, autologous fat grafting and lymph node transplantation showed to have the greatest benefit for patients in terms of quality of life and reduced pain scores. Pulsed radiofrequency demonstrated the highest quality of evidence for energy related procedures. Within the physical therapy interventions, transcutaneous electric nerve stimulation and dry needling showed the greatest benefit. Finally, virtual reality demonstrated the greatest benefit in educational interventions.
{"title":"Nonpharmacological Interventions for Postmastectomy Pain Syndrome-A Systematic Review of the Literature.","authors":"Edmundo Gónima Valero, Cristian D Rodríguez Miranda, Sandra Contreras Arrieta, Maria I Daza Morelli, Daniela Seija Butnaru, Mariana Reyes Carrillo, Laura D Aponte Camacho, Sebastian Amaya","doi":"10.1016/j.clbc.2024.10.007","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.007","url":null,"abstract":"<p><strong>Objective: </strong>Literature regarding nonpharmacological interventions (NPI) for PMPS or CP after mastectomy is scarce and not fully appraised, therefore we conducted this systematic review to explore the current panorama of treatment options.</p><p><strong>Methods: </strong>A systematic review to assess the existing evidence regarding nonpharmacological approaches for PMPS. We reviewed the following databases: PubMed-MEDLINE, Embase, and Ovid (including the Cochrane Database for Clinical studies) using the following search terms: CP, mastectomy, and PMPS, and adjusted the terms depending on the database used. We included observational studies including case reports, cross sectional studies, cohort studies, and clinical trials (randomized or not) that included a NPI to treat PMPS.</p><p><strong>Results: </strong>Total 1061 records were identified. After duplicate elimination, 863 records were screened for eligibility. A total of 717 records were excluded using our criteria, 138 records were sought for retrieval, and 117 full text records were assessed. Finally, 30 studies were included: seven case series, one cross-sectional study, two cohort studies, one case-control study, five nonrandomized clinical trials, ten randomized clinical trials (RCT), one qualitative study, and three systematic reviews of the literature, including two meta analyses, were included.</p><p><strong>Discussion: </strong>Findings suggest that there is a great response of patients to some NPI. Regarding surgical interventions, autologous fat grafting and lymph node transplantation showed to have the greatest benefit for patients in terms of quality of life and reduced pain scores. Pulsed radiofrequency demonstrated the highest quality of evidence for energy related procedures. Within the physical therapy interventions, transcutaneous electric nerve stimulation and dry needling showed the greatest benefit. Finally, virtual reality demonstrated the greatest benefit in educational interventions.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-22DOI: 10.1016/j.clbc.2024.10.002
Xiu Zhang, Peng Zhang, Xiang Chen, Xianyi Liu, Wenwen Liu, Xi Hu, Chengcheng Sun, Xiaochun Wang, Jianhong Shi
Purpose: The deubiquitylase OTUD7B plays a facilitates role in lung tumorigenesis through VEGF protein, but its role in breast cancer remains unclear. In the present study, we proposed to explore the role of deubiquitylase OTUD7B in breast cancer.
Methods: The expression of OTUD7B in breast cancer and adjacent tissues was detected. The role of OTUD7B in cell proliferation and invasion of breast cancer cell lines such as MCF-7 and MDA-MB-453 was explored.
Results: OTUD7B is highly expressed in human breast cancer tissues and its higher expression correlates with better survival of patients. Further mechanistic studies reveal that OTUD7B associates with RASGRF1 and PLCE1 to disrupt RAS signaling pathway. Knockdown of OTUD7B results in decreasing levels of RASGRF1 protein, suppression cell growth and invasion in breast cancer. Collectively, our results reveal a previously unappreciated anti-oncogentic role OTUD7B involved in RAS signaling pathway in breast cancer and indicate that deubiquitylases could induce tumor-suppressing or tumor-promoting activities in a cell- and tissue-dependent context.
{"title":"Deubiquitinase OTUD7B Regulates Cell Proliferation in Breast Cancer.","authors":"Xiu Zhang, Peng Zhang, Xiang Chen, Xianyi Liu, Wenwen Liu, Xi Hu, Chengcheng Sun, Xiaochun Wang, Jianhong Shi","doi":"10.1016/j.clbc.2024.10.002","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.002","url":null,"abstract":"<p><strong>Purpose: </strong>The deubiquitylase OTUD7B plays a facilitates role in lung tumorigenesis through VEGF protein, but its role in breast cancer remains unclear. In the present study, we proposed to explore the role of deubiquitylase OTUD7B in breast cancer.</p><p><strong>Methods: </strong>The expression of OTUD7B in breast cancer and adjacent tissues was detected. The role of OTUD7B in cell proliferation and invasion of breast cancer cell lines such as MCF-7 and MDA-MB-453 was explored.</p><p><strong>Results: </strong>OTUD7B is highly expressed in human breast cancer tissues and its higher expression correlates with better survival of patients. Further mechanistic studies reveal that OTUD7B associates with RASGRF1 and PLCE1 to disrupt RAS signaling pathway. Knockdown of OTUD7B results in decreasing levels of RASGRF1 protein, suppression cell growth and invasion in breast cancer. Collectively, our results reveal a previously unappreciated anti-oncogentic role OTUD7B involved in RAS signaling pathway in breast cancer and indicate that deubiquitylases could induce tumor-suppressing or tumor-promoting activities in a cell- and tissue-dependent context.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1016/j.clbc.2024.10.008
Jan-Willem Henning, Devon J Boyne, Darren R Brenner, Chantelle Carbonell, Simran Shokar, Diana P Granados, Anna Parackal, Winson Y Cheung
Background: Data are needed to improve the current understanding of the epidemiology of patients with high-risk, HER2-negative, early breast cancer (eBC) (hormone receptor positive [HR+]/HER2-negative BC and triple-negative BC [TNBC]).
Patients and methods: This retrospective longitudinal cohort study used real-world, population-level data that included all individuals newly diagnosed with high-risk, HER2-negative eBC in Alberta, Canada, between 2010 and 2019. Data on treatment, laboratory results and pathology findings were collected through electronic health records and administrative databases.
Results: The annual cumulative incidence of high-risk, HER2-negative eBC ranged from 6% to 9% of all incident BC cases. Individuals with TNBC were more likely to be younger, had stage II disease, grade 3 histology and received systemic therapy at a community centre (P < .05) compared to individuals with HR+/HER2-negative eBC. Only 14% of individuals diagnosed in 2010-2017 underwent germline BRCA testing postdiagnosis. Neoadjuvant systemic therapy was given to 37% of individuals. Adjuvant systemic therapy use increased from 77% (2012-2015) to 84% (2019). The 5-year overall survival (OS) from initiation of adjuvant systemic therapy or date of surgery (for individuals who did not receive adjuvant systemic therapy) was 77% (95% CI: 75-79). OS was significantly worse among individuals who were older, had grade 3 histology, had stage III disease, or had nodal involvement (P < .05). OS among individuals with TNBC between 2016 and 2019 who initiated adjuvant capecitabine was markedly worse compared to the overall cohort (2-year OS: 70% vs. 89%).
Conclusion: Outcomes analyses in this high-risk, HER2-negative eBC population suggest a continued unmet clinical need.
背景:需要数据来提高目前对高风险、HER2 阴性、早期乳腺癌(eBC)(激素受体阳性[HR+]/HER2 阴性 BC 和三阴性 BC [TNBC])患者流行病学的了解:这项回顾性纵向队列研究使用了真实世界的人群水平数据,包括2010年至2019年期间加拿大艾伯塔省新诊断出的所有高危、HER2阴性eBC患者。有关治疗、实验室结果和病理结果的数据是通过电子健康记录和行政数据库收集的:高风险、HER2 阴性 eBC 的年累计发病率占 BC 病例总数的 6% 至 9%。与HR+/HER2阴性eBC患者相比,TNBC患者更有可能更年轻、患有II期疾病、组织学分级为3级且在社区中心接受过系统治疗(P < .05)。在2010-2017年期间确诊的患者中,只有14%在确诊后接受了种系BRCA检测。37%的患者接受了新辅助系统治疗。辅助系统疗法的使用率从77%(2012-2015年)增至84%(2019年)。从开始辅助系统治疗或手术日期(未接受辅助系统治疗者)算起的5年总生存率(OS)为77%(95% CI:75-79)。年龄较大、组织学分级为3级、疾病为III期或有结节受累的患者的OS明显较差(P < .05)。与整体队列相比,2016年至2019年期间罹患TNBC并开始卡培他滨辅助治疗的患者的OS明显较差(2年OS:70% vs. 89%):对这一高风险、HER2阴性eBC人群的结果分析表明,临床需求仍未得到满足。
{"title":"Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada.","authors":"Jan-Willem Henning, Devon J Boyne, Darren R Brenner, Chantelle Carbonell, Simran Shokar, Diana P Granados, Anna Parackal, Winson Y Cheung","doi":"10.1016/j.clbc.2024.10.008","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.008","url":null,"abstract":"<p><strong>Background: </strong>Data are needed to improve the current understanding of the epidemiology of patients with high-risk, HER2-negative, early breast cancer (eBC) (hormone receptor positive [HR+]/HER2-negative BC and triple-negative BC [TNBC]).</p><p><strong>Patients and methods: </strong>This retrospective longitudinal cohort study used real-world, population-level data that included all individuals newly diagnosed with high-risk, HER2-negative eBC in Alberta, Canada, between 2010 and 2019. Data on treatment, laboratory results and pathology findings were collected through electronic health records and administrative databases.</p><p><strong>Results: </strong>The annual cumulative incidence of high-risk, HER2-negative eBC ranged from 6% to 9% of all incident BC cases. Individuals with TNBC were more likely to be younger, had stage II disease, grade 3 histology and received systemic therapy at a community centre (P < .05) compared to individuals with HR+/HER2-negative eBC. Only 14% of individuals diagnosed in 2010-2017 underwent germline BRCA testing postdiagnosis. Neoadjuvant systemic therapy was given to 37% of individuals. Adjuvant systemic therapy use increased from 77% (2012-2015) to 84% (2019). The 5-year overall survival (OS) from initiation of adjuvant systemic therapy or date of surgery (for individuals who did not receive adjuvant systemic therapy) was 77% (95% CI: 75-79). OS was significantly worse among individuals who were older, had grade 3 histology, had stage III disease, or had nodal involvement (P < .05). OS among individuals with TNBC between 2016 and 2019 who initiated adjuvant capecitabine was markedly worse compared to the overall cohort (2-year OS: 70% vs. 89%).</p><p><strong>Conclusion: </strong>Outcomes analyses in this high-risk, HER2-negative eBC population suggest a continued unmet clinical need.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1016/j.clbc.2024.10.012
Kadri Altundag
{"title":"Assessing and Comparing the Diagnostic Effectiveness of [<sup>18</sup>F]FDG PET/CT and [<sup>18</sup>F]FDG PET/MRI for Distant Metastases in Breast Cancer Patients With Invasive Lobular Carcinoma Histology: An Ongoing Topic of Debate?","authors":"Kadri Altundag","doi":"10.1016/j.clbc.2024.10.012","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.012","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1016/j.clbc.2024.10.009
Youshi Sun, Lu Gao, Xingtong Zhou, Zihao Wang, Yan Li, Qiang Sun
Background: The appropriateness of BCT for MF/MCBC is debated, with concerns about higher recurrence rates. This study aims to provide an updated systematic review and meta-analysis of LR and survival outcomes for MF/MCBC patients undergoing BCT.
Methods: PubMed, Web of Science, Embase, and the Cochrane Library were searched up to May 2024. Eligible studies included original research articles comparing LR, DFS, or OS in patients with MF/MC or UF breast cancer undergoing BCT or mastectomy. Meta-analyses for LR were conducted using the Mantel-Haenszel method. Published Kaplan-Meier curves for DFS and OS were digitized and aggregated to estimate summary survival curves.
Results: 21 studies were included in the meta-analysis for LR, comprising 28,589 participants, and 7 studies for survival analysis. The meta-analysis revealed that MF/MC breast cancer patients undergoing BCT had a significantly higher LR rate compared to UF patients (OR = 1.76, 95% CI: 1.24-2.49, P = .002), though recent studies indicated comparable LR rates. No significant difference in LR was found between MF/MC patients treated with BCT versus mastectomy (OR = 1.72, 95% CI: 0.96-3.10, P = .07). The estimated 3-, 5-, and 8-year DFS rates were 92.4%, 88.3%, and 84.5%, respectively, while the OS rates were 98.0%, 95.8%, and 91.8%.
Conclusion: BCT for MF/MC breast cancer was associated with higher LR rates compared to UF breast cancer, but the disparity was reducing in recent years. BCT offers comparable LR outcomes to mastectomy in MF/MC patients. Survival outcomes for MF/MC patients treated with BCT were favorable, affirming its oncological safety.
背景:MF/MCBC是否适合接受BCT治疗尚存争议,人们担心复发率会更高。本研究旨在对接受 BCT 的 MF/MCBC 患者的 LR 和生存结果进行最新的系统回顾和荟萃分析:方法:检索了截至 2024 年 5 月的 PubMed、Web of Science、Embase 和 Cochrane Library。符合条件的研究包括比较接受 BCT 或乳房切除术的 MF/MC 或 UF 乳腺癌患者的 LR、DFS 或 OS 的原始研究文章。采用 Mantel-Haenszel 方法对 LR 进行元分析。对已发表的DFS和OS的Kaplan-Meier曲线进行数字化处理并汇总,以估算出汇总生存曲线。结果:21项研究纳入了LR的荟萃分析,包括28589名参与者,7项研究纳入了生存分析。荟萃分析显示,与UF患者相比,接受BCT治疗的MF/MC乳腺癌患者的LR率明显更高(OR = 1.76,95% CI:1.24-2.49,P = .002),尽管最近的研究显示LR率相当。采用 BCT 与乳房切除术治疗的 MF/MC 患者的 LR 无明显差异(OR = 1.72,95% CI:0.96-3.10,P = .07)。估计3年、5年和8年的DFS率分别为92.4%、88.3%和84.5%,而OS率分别为98.0%、95.8%和91.8%:结论:与UF乳腺癌相比,BCT治疗MF/MC乳腺癌的LR率较高,但近年来这种差异正在缩小。BCT对MF/MC患者的LR结果与乳房切除术相当。接受BCT治疗的MF/MC患者的生存率良好,证实了其肿瘤安全性。
{"title":"Local Recurrence and Survival Outcomes of Multifocal/Multicentric Breast Cancer After Breast Conserving Therapy: A systematic Review and Meta-Analysis.","authors":"Youshi Sun, Lu Gao, Xingtong Zhou, Zihao Wang, Yan Li, Qiang Sun","doi":"10.1016/j.clbc.2024.10.009","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.009","url":null,"abstract":"<p><strong>Background: </strong>The appropriateness of BCT for MF/MCBC is debated, with concerns about higher recurrence rates. This study aims to provide an updated systematic review and meta-analysis of LR and survival outcomes for MF/MCBC patients undergoing BCT.</p><p><strong>Methods: </strong>PubMed, Web of Science, Embase, and the Cochrane Library were searched up to May 2024. Eligible studies included original research articles comparing LR, DFS, or OS in patients with MF/MC or UF breast cancer undergoing BCT or mastectomy. Meta-analyses for LR were conducted using the Mantel-Haenszel method. Published Kaplan-Meier curves for DFS and OS were digitized and aggregated to estimate summary survival curves.</p><p><strong>Results: </strong>21 studies were included in the meta-analysis for LR, comprising 28,589 participants, and 7 studies for survival analysis. The meta-analysis revealed that MF/MC breast cancer patients undergoing BCT had a significantly higher LR rate compared to UF patients (OR = 1.76, 95% CI: 1.24-2.49, P = .002), though recent studies indicated comparable LR rates. No significant difference in LR was found between MF/MC patients treated with BCT versus mastectomy (OR = 1.72, 95% CI: 0.96-3.10, P = .07). The estimated 3-, 5-, and 8-year DFS rates were 92.4%, 88.3%, and 84.5%, respectively, while the OS rates were 98.0%, 95.8%, and 91.8%.</p><p><strong>Conclusion: </strong>BCT for MF/MC breast cancer was associated with higher LR rates compared to UF breast cancer, but the disparity was reducing in recent years. BCT offers comparable LR outcomes to mastectomy in MF/MC patients. Survival outcomes for MF/MC patients treated with BCT were favorable, affirming its oncological safety.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}